Another approach is the modification of tumor cells or DCs with genetically engineered viruses expressing various cytokines, including IL-2 (92, 93), IL-12, IL-18 (94, 95), GM-CSF (96), or IFN-β (97) to enhance anti-tumor immunity and protect against tumor re-challenge. This evidence concerns the gene IL18 and neoplasm.